Navigation Links
ViroPharma Incorporated Reports Third Quarter 2008 Financial Results
Date:10/29/2008

br /> For the year 2008, ViroPharma expects the following

-- Net Vancocin sales are expected to be $235 to $245 million;

-- Research and development (R&D) and selling, general and administrative

(SG&A) expenses, excluding the impact of SFAS 123R, are expected to be

$115 to $125 million.

-- The SFAS 123R impact to the above expenses will be approximately 9

million. Including the impact of SFAS 123R, the research and

development (R&D) and sales, general and administrative (SG&A) expenses

are expected to be between $124 and $134 million.

Non-GAAP Disclosures

This press release includes non-GAAP financial information as the Company's projected research and development and marketing, general and administrative expenses has been presented excluding the effect of stock option expense resulting from the application of SFAS 123R. The Company believes that presenting its research and development (R&D) expense and sales, general and administrative (SG&A) expense in this release both with and without the impact of share-based compensation will allow investors to better understand the Company's financial results and how such results compare with the Company's prior results and current guidance.

Conference Call and Webcast

ViroPharma is hosting a live teleconference and webcast with senior management to discuss the financial announcement, guidance, and other business results on October 29, 2008 at 9:00 a.m. Eastern Time. To participate in the conference call, please dial 877-366-0713 (domestic) and 302-607-2000 (international). After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.

Alternatively, the live webcast of the conference call can be accessed via ViroPharma's website at http://www.viropharma.com. Windows Media or Real Player will be needed to access the webcast. An a
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008
2. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
4. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
5. ViroPharma Provides Update on Vancocin(R)
6. ViroPharma Augments Senior Management
7. ViroPharma to Present at the 26th Annual JP Morgan Healthcare Conference
8. ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
9. ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results
10. ViroPharma to Present at the UBS Global Life Sciences Conference
11. ViroPharma to Present at the Maxim Group First Annual Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... from healthy, unrelated donors was safe and effective ... by Clostridium difficile , according to a ... Diseases and available online. Known as fecal ... given via a colonoscope or a nasogastric tube. ... promising treatment more readily available to patients. , ...
(Date:4/23/2014)... O,Shea, M.D., scientific director at the National Institute of ... named the 2014 recipient of the Ross Prize in ... journal Molecular Medicine . The award will be ... of Sciences in Manhattan, followed by scientific presentations by ... of the National Institutes of Health. , The award, ...
(Date:4/23/2014)... WEST LAFAYETTE, Ind. - Purdue University researchers have developed ... a living cell by using tiny gold particles with ... Irudayaraj, professor of agricultural and biological engineering, used gold ... material known as BRCA1 messenger RNA splice variants, which ... The number of these mRNA splice variants in a ...
(Date:4/23/2014)... New Rochelle, NY, April 23, 2014Men whose testosterone falls ... dysfunction and to be overweight and have heart disease ... designed to identify testosterone-deficient men for further testing and ... Journal of Men,s Health , a peer-reviewed publication from ... free on the Journal of Men,s Health ...
(Date:4/23/2014)... of probiotics, antioxidants and other nutritional compounds, more and ... is getting in on the action. But legitimate skepticism ... industry is responding with clinical research to shore up ... Chemical & Engineering News (C&EN), the weekly news ... Bomgardner, a senior editor at C&EN, writes that about ...
Breaking Medicine News(10 mins):Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2
... person's face could unveil whether he or she is a ... smokers.A study by dermatologists, published in The Lancet, shows that ... breaks down collagen in the skin.// ,Collagen is the ... of the skin. When this starts to deteriorate, skin begins ...
... devised that each cigarette cuts on average 12 minutes off ... difference in life expectancy between smokers and non-smokers and an ... smoker might consume in a lifetime. ,The researchers, from ... from a major study of the impact of// smoking carried ...
... of drinks is a common problem for heavy drinkers and ... until now.It may support the potentialities of a night out. ... and the Mayo Clinic in Minnesota say the effect of ... in a study of healthy young adults, that blood vessels ...
... descendants of females who are given a choice to select ... the choice.The research involves the humble fruit fly, but experts ... ,Geneticists from the University of Georgia, led by Dr ... fruit fly, in a vial with one virgin female.// Some ...
... patients who are undergoing androgen deprivation therapy by ... New York Cornell Medical Center say this non ... monotherapy in men who require long-term antiandrogen therapy.//, ... patients with clinically localised prostate cancer and 24 ...
... still a health problem need to ensure their people understand ... Organization (WHO) has said. Partners in WHO's Global Alliance for ... annual meeting. Brazil is one of six countries in the ... others are India, Madagascar, Mozambique, Myanmar and Nepal. ...
Cached Medicine News:
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Trading (OFT) approval condition to the announced tender offer for all ... As a result of the waiver, the transaction is no ... tender offer on January 24, 2014 following the currently scheduled expiration ...
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), through ... of highly sophisticated agro-breeding solutions for plant breeders and ... Company,s board of directors appointed chemistry and pharmaceutical industry ... member of the board. From 1975 to ...
(Date:1/15/2014)... Fla. , Jan. 15, 2014  In an unprecedented effort to ... TB in ambulances and other transport vehicles, an advanced and portable ... rescue personnel for the first time. In order ... with these deadly pathogens, West Palm Beach ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The ACMI™ line of laparoscopic hand instruments is designed to provide a wide selection of popular surgical devices to meet procedural needs....
Medicine Products: